Lisofylline Analogs for Pancreatic Beta-Cell Protection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Type 1 diabetes, such as Lisofylline, face limitations due to lack of oral bioavailability and potency, necessitating the development of novel, potent, and selective agents that can protect pancreatic β-cells and maintain insulin secretory capability.

Innovation Solution

Development of Lisofylline analogs with enhanced potency and oral bioavailability, incorporating nitrogen-containing heterocyclic compounds on the side chain, which can protect pancreatic β-cells and potentially reverse Type 1 diabetes by regenerating beta cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Lisofylline is used to protect pancreatic β-cells, then cell viability is improved, but oral bioavailability is poor

Engineering Contradiction:

Improvecell viabilityVSAvoidoral bioavailability

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent modifies the chemical structure of Lisofylline by changing parameters such as the xanthine core structure and side chain composition to create analogs with improved oral bioavailability while maintaining β-cell protective effects. Specific structural modifications include altering the purine ring system and substituent groups to enhance absorption and metabolic stability.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention develops composite chemical structures combining the active side chain moiety of Lisofylline with modified heterocyclic cores, creating hybrid molecules that integrate the protective mechanism of the original compound with improved pharmacokinetic properties for oral administration.

Inventive Principle:

Principle #40Composite materials

2Reliability

If Lisofylline is used to protect pancreatic β-cells, then cell viability is improved, but potency is relatively weak

Engineering Contradiction:

Improvecell viabilityVSAvoidpotency

Core Design Contradiction:

ReliabilityVSPower

Solution Approach 1:

The patent applies local quality modifications by specifically altering the xanthine core structure and side chain attachments at key positions to enhance binding affinity and biological activity. The modifications focus on the nitrogen-containing heterocyclic regions to improve interaction with target receptors while preserving the essential protective mechanism.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

Structural parameters such as ring substitution patterns, side chain length, and heteroatom positioning are systematically modified to optimize potency. The analogs incorporate enhanced electron distribution and steric properties to strengthen the protective effect against inflammatory cytokine-mediated injury.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If Lisofylline is used to protect pancreatic β-cells, then insulin secretory capability is maintained, but selectivity is insufficient

Engineering Contradiction:

Improveinsulin secretory capabilityVSAvoidselectivity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent enhances selectivity through localized structural modifications at the xanthine core and side chain interface, creating molecules with improved specificity for pancreatic β-cell targets. The modifications optimize hydrogen bonding and hydrophobic interactions to differentiate between β-cell and other cell type receptors.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS8871764B2Lisofylline analogs and methods for use

Publication Date: 2014.10.28 UNIV OF VIRGINIA PATENT FOUND

AI summary

Analogs of a Lisofylline (LSF), and synthetic methods for the preparation of such analogs are provided. The analogs of LSF provided have the ability to protect cell viability, particularly the ability to protect pancreatic β-cells.